Samsung Biologics set to start construction of Plant 5
Samsung Biologics reports earnings surprise in Q2 on vaccine addition - Pulse by Maeil Business News Korea
Company News | Newsroom | SAMSUNG BIOLOGICS
PharmaBoardroom - Samsung Biologics
Pfizer taps Samsung Biologics in manufacturing deals worth $897 million
Samsung Biologics' P4 Super Plant, Songdo, South Korea
Samsung Biologics' focused approach pays off in 2020 - KED Global
Samsung Biologics boasts top-tier production capacity at BIO International
Samsung Biologics | The Leading Global CDMO with End-to-End Services
Samsung Biologics Page 1 of 0 | ISM
IPO puts value of Samsung BioLogics at $8.2B | Fierce Pharma
Samsung Biologics buys Biogen's stake in Samsung Bioepis for $2.3B | BioWorld
Samsung Biologics Customer Story | SailPoint
Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
Samsung Biologics - Wikipedia
Samsung Biologics Aims to Create Super-wide Gap in CDMO Field - Businesskorea
Samsung Biologics Plans to Accelerate the Opening of its New Fifth Plant
Company News | Newsroom | SAMSUNG BIOLOGICS
Samsung BioLogics sees sales rise but profit fall as it continues expansion | Fierce Pharma
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab | World Pharma Today
Samsung Biologics signs $409 mil. CMO deal with Pfizer - The Korea Times
Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
Our Story | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics to double production by 2032; eyes ADCs, M&As - KED Global
Company News | Newsroom | SAMSUNG BIOLOGICS
Our Story | Newsroom | SAMSUNG BIOLOGICS
Samsung Biologics acquires Samsung Bioepis joint venture for $2.3bn
